Impact of antiretroviral protocols on dynamics of AIDS progression markers
Open Access
- 1 February 2002
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 86 (2) , 119-124
- https://doi.org/10.1136/adc.86.2.119
Abstract
Aims: To assess the “real life” effectiveness of different antiretroviral therapies (ART). Methods: A retrospective multicentre observational study in 150 HIV-1 vertically infected children on the progression to AIDS (study A), and in 61 HIV-1 infected children on the evolution of the most relevant markers of progression (study B). All children were categorised into four groups: untreated (NT); on monotherapy (MT); on combination therapy (dual-ART); and on potent ART (HAART). Results: No child in the HAART group progressed to AIDS, whereas 14 children in the NT and seven in the MT groups progressed to AIDS, respectively, the differences being statistically significant. There was a mean increase of 8 units of %CD4+ per year; this was greater in the HAART group than in the other groups. The mean decrease in viral load was 0.65 log10 copies/ml per year; this was greater in the HAART group than in the NT and MT groups. The HAART group had the lowest probability of returning to baseline %CD4+ and viral load. Conclusion: Potent ART had the greatest protective effect against progression to AIDS in this observational study.Keywords
This publication has 26 references indexed in Scilit:
- Correlation of Viral Load and CD8 T-Lymphocytes with Development of Neurological Manifestations in Vertically HIV-1-Infected Infants. A Prospective Longitudinal StudyNeuropediatrics, 1999
- Early Language Development in Children Exposed to or Infected With Human Immunodeficiency VirusPediatrics, 1998
- Longitudinal evaluation of severely anemic children in KenyaAIDS, 1997
- Potent HIV Protease Inhibitors Containing a Novel (Hydroxyethyl)amide IsostereJournal of Medicinal Chemistry, 1997
- Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor.Journal of Clinical Investigation, 1997
- Combination Treatment with Zidovudine, Didanosine, and Nevirapine in Infants with Human Immunodeficiency Virus Type 1 InfectionNew England Journal of Medicine, 1997
- The Relationship between Serum Human Immunodeficiency Virus Type 1 (HIV‐1) RNA Level, CD4 Lymphocyte Percent, and Long‐Term Mortality Risk in HIV‐1—Infected ChildrenThe Journal of Infectious Diseases, 1997
- A Multicenter Trial of Oral Zidovudine in Children with Advanced Human Immunodeficiency Virus DiseaseNew England Journal of Medicine, 1991
- Dideoxyinosine in Children with Symptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1991
- Effect of Continuous Intravenous Infusion of Zidovudine (AZT) in Children with Symptomatic HIV InfectionNew England Journal of Medicine, 1988